HT
ABCL icon

HAP Trading’s AbCellera Biologics ABCL Stock Holding History

HAP Trading’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,800
Closed -$48K – 1896
2022
Q1 		$48K Sell
11,800
-300
-2% -$2.84K ﹤0.01% 1272
2021
Q4 		$60K Sell
12,100
-10,700
-47% -$162K ﹤0.01% 1396
2021
Q3 		$38K Buy
+22,800
New +$403K ﹤0.01% 1595

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

HAP Trading's ABCL Position: Q3 2021 in Review

HAP Trading sold out of AbCellera Biologics (ABCL) in Q3 2021, closing a stake of 11,474 shares — an estimated $203K sold.

HAP Trading first reported a position in ABCL in Q2 2021 and held it in 1 quarter. The position peaked at $252K in Q2 2021. 116 funds tracked by Wall St. Rank hold ABCL as of Q3 2021.

  • HAP Trading reported no remaining AbCellera Biologics position as of Q3 2021 after selling out during the quarter.
  • HAP Trading sold 11,474 AbCellera Biologics shares in Q3 2021, an estimated $203K.
  • HAP Trading first reported a position in AbCellera Biologics in Q2 2021 and held it in 1 quarter.
  • HAP Trading's AbCellera Biologics position peaked at $252K in Q2 2021.
  • 116 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2021.

Based on HAP Trading's 13F filing for Q3 2021, filed 10 Nov 2021.